BRPI0610912A2 - anticorpos anti-il2 - Google Patents

anticorpos anti-il2

Info

Publication number
BRPI0610912A2
BRPI0610912A2 BRPI0610912-8A BRPI0610912A BRPI0610912A2 BR PI0610912 A2 BRPI0610912 A2 BR PI0610912A2 BR PI0610912 A BRPI0610912 A BR PI0610912A BR PI0610912 A2 BRPI0610912 A2 BR PI0610912A2
Authority
BR
Brazil
Prior art keywords
human
monoclonal antibody
humanized monoclonal
binding
amino acid
Prior art date
Application number
BRPI0610912-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Patrick Baeuerle
John Lumsden
Stefan Pflanz
Tobias Raum
Joerg Volkland
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag filed Critical Micromet Ag
Publication of BRPI0610912A2 publication Critical patent/BRPI0610912A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
BRPI0610912-8A 2005-06-01 2006-05-31 anticorpos anti-il2 BRPI0610912A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05011845 2005-06-01
PCT/EP2006/005194 WO2006128690A1 (en) 2005-06-01 2006-05-31 Anti-il2 antibodies

Publications (1)

Publication Number Publication Date
BRPI0610912A2 true BRPI0610912A2 (pt) 2008-12-02

Family

ID=37025008

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610912-8A BRPI0610912A2 (pt) 2005-06-01 2006-05-31 anticorpos anti-il2

Country Status (15)

Country Link
US (1) US7964707B2 (enExample)
EP (1) EP1888644A1 (enExample)
JP (1) JP5414271B2 (enExample)
KR (1) KR101340559B1 (enExample)
CN (1) CN101189265B (enExample)
AU (1) AU2006254333B2 (enExample)
BR (1) BRPI0610912A2 (enExample)
CA (1) CA2609234C (enExample)
IL (1) IL187316A0 (enExample)
MX (1) MX2007014565A (enExample)
NO (1) NO20076568L (enExample)
NZ (1) NZ563213A (enExample)
RU (1) RU2425054C2 (enExample)
WO (1) WO2006128690A1 (enExample)
ZA (1) ZA200709456B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG173577A1 (en) * 2009-03-16 2011-09-29 Cephalon Australia Pty Ltd Humanised antibodies with anti-tumour activity
EP2496257A4 (en) * 2009-11-05 2013-02-27 Cephalon Australia Pty Ltd TREATMENT OF CANCER CHARACTERIZED BY THE MUTATION OF KRAS OR BRAF GENES
CN104220453B (zh) * 2012-04-03 2018-03-09 诺沃姆德治疗公司 人源化的嵌合抗因子c3抗体及其用途
US10011652B2 (en) 2013-12-12 2018-07-03 Umc Utrecht Holding B.V. Immunoglobulin-like molecules directed against fibronectin-EDA
CN105980556B (zh) * 2013-12-26 2020-10-09 田边三菱制药株式会社 人抗il－33中和单克隆抗体
ES2989669T3 (es) * 2014-07-10 2024-11-27 Univ Zuerich Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana
AU2016340989B2 (en) * 2015-10-23 2023-09-14 Pfizer Inc. Anti-IL-2 antibodies and compositions and uses thereof
MA43859A (fr) 2016-01-11 2018-11-21 Novartis Ag Anticorps monoclonaux humainisés immunostimulants dirigés contre l'interleukine -2 humaine, et leurs protéines de fusion
TW201811824A (zh) * 2016-07-06 2018-04-01 美商西建公司 具有低免疫原性之抗體及其用途
MX2019003543A (es) 2016-09-28 2019-06-17 Xoma Us Llc Anticuerpos que se fijan al interleucina-2 y sus usos.
JP7057980B2 (ja) * 2017-05-25 2022-04-21 インスティテュート フォー ベーシック サイエンス 抗－ヒトインターロイキン－２抗体及びその用途
EP3677281A4 (en) 2017-08-31 2021-05-12 Mitsubishi Tanabe Pharma Corporation THERAPEUTIC AGENT CONTAINING AN IL-33 ANTAGONIST TO TREAT ENDOMETRIOSIS
ES3037019T3 (en) * 2019-06-10 2025-09-26 Shandong Boan Biotechnology Co Ltd Anti-cd25 antibody and application thereof
US20240376171A1 (en) 2021-03-30 2024-11-14 Hoffmann-La Roche Inc. Protease-activated polypeptides
CN116284380A (zh) * 2021-05-14 2023-06-23 厦门柏慈生物科技有限公司 白细胞介素2结合分子、其衍生物、试剂盒及其生产方法和用途
CN119948048A (zh) 2022-09-29 2025-05-06 豪夫迈·罗氏有限公司 蛋白酶活化的多肽
CN115850471A (zh) * 2022-10-13 2023-03-28 深圳市百士通科技开发有限公司 一种抗人il-2单克隆抗体及其应用
CN119661706B (zh) * 2024-01-31 2025-11-28 康立泰生物医药(青岛)有限公司 一种抗人白介素2抗体及其应用
CN118515762B (zh) * 2024-07-23 2024-11-01 北京百普赛斯生物科技股份有限公司 特异性结合il-2的抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19651443A1 (de) * 1996-12-11 1998-06-18 Hoechst Ag Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
AU2001274939A1 (en) * 2000-05-24 2001-12-03 Smith Kline Beecham Corporation Sialoadhesin factor-3 antibodies
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
DK1562968T3 (da) * 2001-11-14 2013-10-28 Janssen Biotech Inc Anti-il-6-antistoffer, sammensætninger, fremgangsmåder og anvendelser
NZ540555A (en) * 2002-11-15 2008-04-30 Genmab As Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
KR101166012B1 (ko) * 2003-08-13 2012-07-23 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 프리온-특이적 펩티드 시약

Also Published As

Publication number Publication date
AU2006254333B2 (en) 2011-02-17
AU2006254333A1 (en) 2006-12-07
JP2008542321A (ja) 2008-11-27
RU2425054C2 (ru) 2011-07-27
RU2007143996A (ru) 2009-07-20
CN101189265B (zh) 2012-07-04
EP1888644A1 (en) 2008-02-20
NO20076568L (no) 2008-02-19
CA2609234C (en) 2014-04-22
JP5414271B2 (ja) 2014-02-12
CN101189265A (zh) 2008-05-28
US20080317746A1 (en) 2008-12-25
CA2609234A1 (en) 2006-12-07
KR20080032046A (ko) 2008-04-14
WO2006128690A1 (en) 2006-12-07
MX2007014565A (es) 2008-02-11
US7964707B2 (en) 2011-06-21
KR101340559B1 (ko) 2013-12-11
NZ563213A (en) 2009-07-31
ZA200709456B (en) 2008-08-27
IL187316A0 (en) 2008-04-13

Similar Documents

Publication Publication Date Title
BRPI0610912A2 (pt) anticorpos anti-il2
UY33089A (es) PROTEÍNAS DE ENLACE A ANTÍGENOS HUMANAS QUE ENLAZAN B(beta)-KLOTHO, RECEPTORES FGF Y COMPLEJOS DE LOS MISMOS
CL2012003245A1 (es) Proteína de unión a antígeno aislada que se une a linfopoyetina estromal tímica (tslp); composición que comprende una proteína de unión a antígeno que une tslp correspondiente a un anticuerpo humano anti-tslp.
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
CY1121536T1 (el) Ανθρωπινα αντισωματα εναντι-αλφα-συνουκλεϊνης
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
BRPI0611414B8 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao tweak humano, composição farmacêutica e seus usos
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
CY1120951T1 (el) Ανθρωπινα αντισωματα enanti-tau
CR20120587A (es) Moléculas de unión al antígeno que fijan egfr, vectores que las codifican y uso de las mismas
CO6251325A2 (es) Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr)
BR122018012430B8 (pt) anticorpo monoclonal que se liga a pcsk9 humana, e, composição farmacêutica
EP4065164A4 (en) ANTIBODIES AGAINST CD3 AND BCMA AND BISPECIFIC BINDING PROTEINS PRODUCED THEREOF
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
CR8958A (es) Anticuerpos Anti-5T4 humanizados y conjugados de anticuerpos anti-5T4/caliqueamicina
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
CY1112456T1 (el) Αντισωματα υψηλης συγγενειας στον υποδοχεα της ανθρωπινης ιl-6
BRPI0710645A2 (pt) Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos
HUE037642T2 (hu) Humán cd134 (ox40) humán monoklonális antitest és eljárások annak elõállítására és alkalmazására
CR20130152A (es) Proteínas de la unión a il-12/p40 (divisional 9599)
BRPI0607486A2 (pt) anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos
BR112022026401A2 (pt) Conjugados anticorpo-fármaco compreendendo anticorpos anti-b7-h3
NO20080800L (no) Kimaere antistoffer med New World primat regioner
EA200870208A1 (ru) Конструкт однодоменного антитела

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: MICROMET AG (DE)

Free format text: A FIM DE ATENDER AS ALTERACOES DE NOME REQUERIDAS ATRAVES DA PETICAO NO 20120113062/RJ, DE 06/12/2012, E NECESSARIO APRESENTAR MAIS UMA GUIA RELATIVA A SEGUNDA ALTERACAO DE NOME, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25D Requested change of name of applicant approved

Owner name: MICROMET GMBH (DE)

B25D Requested change of name of applicant approved

Owner name: AMGEN RESEARCH (MUNICH) GMBH (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]